HyTest press release first half of fiscal year 2011
06/16/2011

For the first half of the fiscal year 2011, HyTest reported revenues of 5,4 million euros, which is an increase from the 4,7 million euros reported for the same period in 2010. Operating income was high 2,1 million euros - in the percents 39%. Because of continuing profitable growth HyTest has been able to expand its international operations.

Online PR News – 16-June-2011 – – HyTest revenue increased 15 %

HyTest Ltd. is a biotechnology-oriented company based in Turku, Finland, that manufactures and markets high-quality immunological reagents for industrial and research applications. HyTest has customers in all continents. For the first half of the fiscal year 2011, HyTest reported revenues of 5,4 million euros, which is an increase from the 4,7 million euros reported for the same period in 2010. Operating income was high 2,1 million euros - in the percents 39%. Because of continuing profitable growth HyTest has been able to expand its international operations.

During the fist half of the fiscal year the biggest market for HyTest was USA representing 43% of total sales even the dollar was quite weak. Other important markets were EU countries (Great Britain 11% and Germany 10%) and Asia (China 6% and Japan 6%).

Sales of cardiac markers increased significantly during the period and especially troponin-products sales grew remarkably. Also sales of infectious reagents and diabetes products were increasing. By contacting diagnostic companies actively and being visible in the international scientific publications HyTest has been able to grow profitably in the demanding global economic environment.

HyTest manufactures high quality monoclonal antibodies and antigens for industrial and research customers. HyTest is a leading provider of several reagents, such as antibodies and antigens of the troponin I, troponin complex and influenza A and B.